Hematology and Oncology Book

http://www.fpnotebook.com/

Fondaparinux

Aka: Fondaparinux, Arixtra
Advertisement
  1. Mechanism
    1. Heparin derivative
    2. Binds activated factor X (Factor Xa)
  2. Indications: Orthopedic Perioperative DVT Prophylaxis
    1. Hip Fracture
    2. Hip replacement
    3. Knee replacement
  3. Contraindications (due to bleeding risk)
    1. Severe renal Impairment
    2. Weight less than 110 pounds
  4. Dosing
    1. Prophylaxis: DVT
      1. Arixtra 2.5 mg SQ daily
    2. Therapeutic: Bridging for DVT or PE to Warfarin
      1. Weight <50 Kg: 5 mg SQ daily
      2. Weight 50-100 Kg: 7.5 mg SQ daily
      3. Weight >100 Kg: 10 mg SQ daily
  5. Complications
    1. Bleeding
      1. Higher risk than Low Molecular Weight Heparin
    2. Spinal thrombosis with risk of paralysis
      1. Associated with concurrent spinal anesthetic
  6. Efficacy
    1. Lower perioperative DVT and thromboembolism Incidence in hip surgery
  7. References
    1. Eriksson (2001) N Engl J Med 345:1298-304
    2. Turpie (2004) Chest 126:501-8
Medication Costs
Arixtra (on 2/9/2012 at DrugStore.com)
Arixtra 2.5mg/0.5ml Solution 0.5ml Syringe #10 for $593.04 ($59.30/unit)
Arixtra 7.5mg/0.6ml Solution 0.6ml Syringe #1 for $140.09 ($140.09/unit)
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

Arixtra (C1099665)

Concepts Carbohydrate (T118) , Pharmacologic Substance (T121)
MSH C438268
English Arixtra, arixtra, Sanofi Synthelabo brand of fondaparinux sodium, Sanofi brand of fondaparinux sodium
Sources
Derived from the NIH UMLS (Unified Medical Language System)


fondaparinux (C1098510)

Definition (NCI) A drug used to prevent blood clots from forming inside blood vessels in the leg. It is being studied in the prevention of blood clots in some cancer patients, including women having surgery for cancer of the reproductive tract. It is a type of anticoagulant.
Definition (NCI) A drug used to prevent blood clots from forming inside blood vessels in the leg. It is being studied in the prevention of blood clots in some cancer patients, including women having surgery for cancer of the reproductive tract. It is a type of anticoagulant.
Definition (NCI) A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.
Concepts Carbohydrate (T118) , Pharmacologic Substance (T121)
MSH C438268
SnomedCT 395236007
English fondaparinux [Chemical/Ingredient], fondaparinux, Fondaparinux, Fondaparinux (product), FONDAPARINUX
Spanish fondaparinux (producto), fondaparinux
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree